JP2008024603A - Complex powder of vitamin e and proline and method for producing the same - Google Patents
Complex powder of vitamin e and proline and method for producing the same Download PDFInfo
- Publication number
- JP2008024603A JP2008024603A JP2006195602A JP2006195602A JP2008024603A JP 2008024603 A JP2008024603 A JP 2008024603A JP 2006195602 A JP2006195602 A JP 2006195602A JP 2006195602 A JP2006195602 A JP 2006195602A JP 2008024603 A JP2008024603 A JP 2008024603A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- proline
- powder
- trade name
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
本発明は、ビタミンＥとプロリンを有機溶媒中で攪拌することによって、ビタミンＥとプロリンの複合体を形成させ、有機溶媒を留去、乾燥させて得られるビタミンＥ含量が高く、且つ、流動性の良い粉末とその製造方法に関する。 In the present invention, vitamin E and proline are stirred in an organic solvent to form a complex of vitamin E and proline, and the organic solvent is distilled off and dried to obtain a high vitamin E content and fluidity. The present invention relates to a good powder and a method for producing the same.
粘稠で油状であるビタミンＥは、人を対象とした試験において、心筋梗塞のような冠状動脈疾患などの一次予防（Lancet 356:1213-1218,2000（非特許文献１））に対して、前立腺癌の予防（J Natl Cancer Inst 90:440-6,1998（非特許文献２））に対して、さらにはアルツハイマーの認識機能の衰えの抑制（Dimentia 1:134-142,1987（非特許文献３））に対して有効であると判断されている。上記以外の疾患に対しても、ビタミンＥ単独、あるいはビタミンＣや亜鉛などと併用して摂取することによって、予防効果があるとの文献が多数ある。 Vitamin E, which is viscous and oily, is used for primary prevention of coronary artery disease such as myocardial infarction (Lancet 356: 1213-1218, 2000 (Non-Patent Document 1)) in human subjects. For prevention of prostate cancer (J Natl Cancer Inst 90: 440-6,1998 (Non-Patent Document 2)) and further suppression of decline in Alzheimer's cognitive function (Dimentia 1: 134-142,1987 (Non-Patent Document 2) 3)) is determined to be effective. There are a number of documents that have a preventive effect on diseases other than those mentioned above by ingesting vitamin E alone or in combination with vitamin C or zinc.
しかしながらビタミンＥは、常温で油状であり、さらには脂溶性で粘性が極めて高いため、医薬品及び食品へ用いる際には工夫を要する。 However, vitamin E is oily at room temperature, and is fat-soluble and extremely viscous.
一例としては、ビタミンＥを粉末へと形態変化させることであり、粉末にすることによって、容易に医薬品及び食品素材へ均一に混合することができ、商品へと加工する上で極めて有効な方法である。 An example is changing the form of vitamin E into powder, and by making it into powder, it can be easily mixed uniformly into pharmaceuticals and food materials, and is an extremely effective method for processing into products. is there.
ゆえに、ビタミンＥを粉末にする特許が多数あり、例えば乳化剤、ゼラチン及びカゼインナトリウム等のタンパク質、アラビアガム等のガム類、単糖及び二糖等の糖類、糖アルコール、サポニン、化工澱粉及びデキストリン等の多糖類を単独あるいは複合させて用いることで乳化粉末にする特許（特開昭６０−１７８８８２号公報（特許文献１）、特開昭６１−６０６１９号公報（特許文献２）、特開昭６４−６１４１７号公報（特許文献３）、特開平８−１４３４５６号公報（特許文献４）、特開平１０−１２７２５８号公報（特許文献５）、特開平１１−１９３２２９号公報（特許文献６）、特開２０００−２４７８６９号公報（特許文献７）、特開２００４−７５６００号公報（特許文献８））などが報告されている。 Therefore, there are many patents for powdering vitamin E, such as emulsifiers, proteins such as gelatin and sodium casein, gums such as gum arabic, saccharides such as monosaccharides and disaccharides, sugar alcohols, saponins, modified starches and dextrins, etc. Patents to make an emulsified powder by using these polysaccharides alone or in combination (Japanese Patent Application Laid-Open No. 60-178882 (Patent Document 1), Japanese Patent Application Laid-Open No. 61-60619 (Patent Document 2), Japanese Patent Application Laid-Open No. JP-A-61417 (Patent Document 3), JP-A-8-143456 (Patent Document 4), JP-A-10-127258 (Patent Document 5), JP-A-11-193229 (Patent Document 6), JP 2000-247869 (Patent Document 7), JP-A-2004-75600 (Patent Document 8)) and the like have been reported.
しかしながら乳化粉末による方法では、何れもビタミンＥを高含有させた粉末とするには困難であり、さらには高含有させると粉体の流動性が非常に悪くなるという欠点を有していた。 However, any of the methods using emulsified powder has a drawback that it is difficult to obtain a powder containing a high amount of vitamin E, and further, the fluidity of the powder becomes very poor when the content is high.
本発明の課題は、常温で油状であり、脂溶性で粘性が極めて高いビタミンＥを、ビタミンＥ含量が高く、且つ、流動性の良い粉末を見出し製造することである。 An object of the present invention is to find and produce a vitamin E that is oily at room temperature, is fat-soluble and has extremely high viscosity, and has a high vitamin E content and good fluidity.
本発明者は、上記課題を達成するために鋭意検討を重ねた結果、ビタミンＥとプロリンと有機溶媒を配合し、室温乃至加熱しながら攪拌することによってビタミンＥとプロリンの複合体を形成させ、有機溶媒を留去、乾燥させることで、ビタミンＥ含量が高く、且つ、流動性の良い粉末になることを見出し、本発明を完成するに至った。 As a result of intensive studies to achieve the above-mentioned problems, the present inventor blended vitamin E, proline and an organic solvent, and formed a complex of vitamin E and proline by stirring while stirring at room temperature or heating, By distilling off the organic solvent and drying, it was found that the powder had high vitamin E content and good fluidity, and the present invention was completed.
すなわち本発明は、
（１）有機溶媒中で、ビタミンＥとプロリンを攪拌することによって複合体を形成し、有機溶媒を留去、乾燥させて得られるビタミンＥ含有粉末、
（２）ビタミンＥに対するプロリンの重量比が、１：０．２７〜１：０．６７であることを特徴とする（１）記載のビタミンＥ含有粉末、
（３）有機溶媒中で、ビタミンＥとプロリンを攪拌することによって複合体を形成し、有機溶媒を留去、乾燥させることを特徴とするビタミンＥ含有粉末の製造方法、
（４）ビタミンＥに対するプロリンの重量比が、１：０．２７〜１：０．６７であることを特徴とする（３）記載のビタミンＥ含有粉末の製造方法
に関するものである。
That is, the present invention
(1) A vitamin E-containing powder obtained by forming a complex by stirring vitamin E and proline in an organic solvent, distilling off the organic solvent and drying;
(2) The vitamin E-containing powder according to (1), wherein the weight ratio of proline to vitamin E is 1: 0.27 to 1: 0.67,
(3) A method for producing a vitamin E-containing powder characterized in that a complex is formed by stirring vitamin E and proline in an organic solvent, and the organic solvent is distilled off and dried.
(4) The weight ratio of proline to vitamin E is 1: 0.27 to 1: 0.67, and relates to the method for producing a vitamin E-containing powder according to (3).
本発明者が、ビタミンＥの粉末化にあたって、ビタミンＥと混合させる物質として、食品添加物の一種から選択すべく検討したところ、アミノ酸が好ましいと判断した。 When the present inventor studied to select one kind of food additive as a substance to be mixed with vitamin E in powdering vitamin E, it was determined that an amino acid is preferable.
しかし、アミノ酸も多種あるところいろいろ実験を重ねた結果、プロリンのみが粉末化可能であることを見出し、本発明を完成させた。 However, as a result of repeating various experiments in a variety of amino acids, it was found that only proline can be powdered, and the present invention was completed.
本発明で用いるビタミンＥは、大豆及び菜種などの種子あるいはパーム油脂から抽出精製された天然ビタミンＥ、あるいは合成ビタミンＥであり、ｄ−α−トコフェロール、ｄ−β−トコフェロール、ｄ−γ−トコフェロール、ｄ−δ−トコフェロール、ｄ−α−トコトリエノール、ｄ−β−トコトリエノール、ｄ−γ−トコトリエノール、ｄ−δ−トコトリエノール及びｄｌ−α−トコフェロールの内１または２以上の混合物である。該ビタミンＥは、常温で油状であり、さらには脂溶性で粘性が極めて高い。 Vitamin E used in the present invention is natural vitamin E extracted from seeds such as soybean and rapeseed or palm oil or synthetic vitamin E, and is d-α-tocopherol, d-β-tocopherol, d-γ-tocopherol. , D-δ-tocopherol, d-α-tocotrienol, d-β-tocotrienol, d-γ-tocotrienol, d-δ-tocotrienol and dl-α-tocopherol. The vitamin E is oily at room temperature, and is fat-soluble and extremely viscous.
本発明で用いるプロリンは、人体を形成するタンパク質の構成成分である２０種類のアミノ酸の一種であり、皮膚などを構成するコラーゲンの主要成分である。一般的な性質は、複素環を有した構造であり、弱い甘味を呈し、脂肪分解酵素リパーゼの活性化、コラーゲン合成促進活性及び表皮細胞増殖促進活性などの生理活性を示し、さらには即効性のエネルギー源となる。 Proline used in the present invention is one of 20 amino acids that are constituents of proteins that form the human body, and is a major component of collagen that constitutes the skin and the like. A general property is a structure having a heterocyclic ring, which exhibits weak sweetness, exhibits physiological activities such as lipolytic enzyme lipase activation, collagen synthesis promoting activity and epidermal cell proliferation promoting activity, and also has an immediate effect. It becomes an energy source.
ビタミンＥとプロリンの比率は、重量換算でビタミンＥ：プロリン＝１：０．１〜１：１０であることが好ましく、より好ましくは、ビタミンＥ：プロリン＝１：０．２７〜１：０．６７である。本発明は、ビタミンＥ含量が高く、且つ、流動性の良い粉末を得ることが目的であり、重量換算でビタミンＥが１に対してプロリンが０．２７よりも低い場合には、粉体の流動性が悪くなり、重量換算でビタミンＥが１に対してプロリンが０．６７よりも高い場合には、ビタミンＥの含量が低下してくる。 The ratio of vitamin E to proline is preferably vitamin E: proline = 1: 0.1 to 1:10 in terms of weight, more preferably vitamin E: proline = 1: 0.27 to 1: 0. 67. The object of the present invention is to obtain a powder having a high vitamin E content and good fluidity. When vitamin E is 1 and proline is lower than 0.27 in terms of weight, When the fluidity is deteriorated and vitamin E is 1 in weight conversion and proline is higher than 0.67, the content of vitamin E decreases.
本発明で用いる有機溶媒は、メタノール、エタノール、プロパノール及びブタノール等のアルコール類であり、ビタミンＥとプロリンを溶解させるものであるならば何れを用いてもかまわないが、食品への用途を考えると、エタノールを用いることが好ましい。 The organic solvent used in the present invention is alcohols such as methanol, ethanol, propanol and butanol, and any of them can be used as long as it dissolves vitamin E and proline. It is preferable to use ethanol.
エタノール量は、ビタミンＥとプロリンの仕込み量に対して１０倍量（Ｖ／Ｗ）以上であることが好ましい。 The amount of ethanol is preferably 10 times the amount (V / W) or more of the amount of vitamin E and proline charged.
本発明のビタミンＥ含量が高く、且つ、流動性の良い粉末は、以下に述べる方法で製造ができるが、これに限定されるものではない。ビタミンＥ、プロリン及びエタノールを、加温あるいは加熱装置が取り付けられているタンクに所定量を入れ、加温しながら所定時間攪拌した後、エタノールを留去し、次いで乾燥させる。エタノールの留去は、蒸留あるいは減圧蒸留装置などの一般的な装置を用いて行い、粉末の乾燥は、噴霧乾燥、ドラム乾燥、ベルト乾燥あるいは凍結乾燥機などの一般的な装置を用いて行うことができる。 The powder having high vitamin E content and good fluidity of the present invention can be produced by the method described below, but is not limited thereto. A predetermined amount of vitamin E, proline and ethanol are put into a tank equipped with a heating or heating device and stirred for a predetermined time while heating, and then ethanol is distilled off and then dried. Evaporation of ethanol should be performed using a general apparatus such as distillation or vacuum distillation apparatus, and powder drying should be performed using a general apparatus such as spray drying, drum drying, belt drying or freeze dryer. Can do.
かくして得られる粉末は、ビタミンＥ含量が高く、粉体の流動性が良い。この粉末は、ビタミンＥが心筋梗塞のような冠状動脈疾患などの一次予防、前立腺癌の予防、さらにはアルツハイマーの認識機能の衰えの抑制に対して有効であることから、その生理的機能を期待した使用方法に採用できる。 The powder thus obtained has a high vitamin E content and good powder flowability. This powder is expected to have physiological functions because vitamin E is effective for primary prevention of coronary artery disease such as myocardial infarction, prevention of prostate cancer, and suppression of decline in Alzheimer's cognitive function. It can be adopted for the usage method.
本発明によって、ビタミンＥ含量が高く、且つ、流動性の良い粉末を作ることができ、医薬品及び食品の製造に適した粉末にすることができる。 According to the present invention, a powder having a high vitamin E content and good fluidity can be produced, and a powder suitable for production of pharmaceuticals and foods can be obtained.
以下に本発明の実施例及び比較例を挙げて、より詳細に説明するが、本発明はそれらに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples, but the present invention is not limited thereto.
表１の配合に準じ、ビタミンＥ（商品名：ｄ−α−トコフェロール タマ生化学(株)製）５ｇ、プロリン（商品名：Ｌ（−）−プロリン 和光純薬工業(株)製）５ｇ、エタノール１８０ｍｌをナス型フラスコに量りとり、７５℃で３時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を１０ｇ得た。 According to the composition in Table 1, 5 g of vitamin E (trade name: d-α-tocopherol manufactured by Tama Seikagaku Co., Ltd.), 5 g of proline (trade name: L (−)-proline, manufactured by Wako Pure Chemical Industries, Ltd.), 180 ml of ethanol was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure, followed by drying under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、ビタミンＥとプロリンの比が１：１であり、ビタミンＥの含量が５０％であった。 In this example, the ratio of vitamin E to proline was 1: 1, and the content of vitamin E was 50%.
表１の配合に準じ、ビタミンＥ（商品名：ｄ−α−トコフェロール タマ生化学(株)製）６ｇ、プロリン（商品名：Ｌ（−）−プロリン 和光純薬工業(株)製）４ｇ、エタノール１５０ｍｌをナス型フラスコに量りとり、７５℃で３時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を１０ｇ得た。 According to the composition of Table 1, vitamin E (trade name: d-α-tocopherol manufactured by Tama Biochemical Co., Ltd.) 6 g, proline (trade name: L (−)-proline manufactured by Wako Pure Chemical Industries, Ltd.) 4 g, 150 ml of ethanol was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure, followed by drying under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、ビタミンＥとプロリンの比が１：０．６７であり、ビタミンＥの含量が６０％であった。 In this example, the ratio of vitamin E to proline was 1: 0.67, and the content of vitamin E was 60%.
表１の配合に準じ、ビタミンＥ（商品名：ｄ−α−トコフェロール タマ生化学(株)製）７ｇ、プロリン（商品名：Ｌ（−）−プロリン 和光純薬工業(株)製）３ｇ、エタノール１００ｍｌをナス型フラスコに量りとり、７５℃で３時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を１０ｇ得た。 According to the composition of Table 1, vitamin E (trade name: d-α-tocopherol manufactured by Tama Biochemical Co., Ltd.) 7 g, proline (trade name: L (−)-proline manufactured by Wako Pure Chemical Industries, Ltd.) 3 g, 100 ml of ethanol was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure, followed by drying under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、ビタミンＥとプロリンの比が１：０．４３であり、ビタミンＥの含量が７０％であった。 In this example, the ratio of vitamin E to proline was 1: 0.43, and the content of vitamin E was 70%.
表１の配合に準じ、ビタミンＥ（商品名：ｄ−α−トコフェロール タマ生化学(株)製）７．８ｇ、プロリン（商品名：Ｌ（−）−プロリン 和光純薬工業(株)製）２．２ｇ、エタノール１００ｍｌをナス型フラスコに量りとり、７５℃で３時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を１０ｇ得た(図１)。 7.8 g of vitamin E (trade name: d-α-tocopherol Tama Seikagaku Co., Ltd.), proline (trade name: L (-)-proline, manufactured by Wako Pure Chemical Industries, Ltd.) 2.2 g and 100 ml of ethanol were weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder (FIG. 1).
本実施例は、ビタミンＥとプロリンの比が１：０．２８であり、ビタミンＥの含量が７８％であった。 In this example, the ratio of vitamin E to proline was 1: 0.28, and the content of vitamin E was 78%.
[比較例１]
表１の配合に準じ、ビタミンＥ（商品名：ｄ−α−トコフェロール タマ生化学(株)製）９．１ｇ、プロリン（商品名：Ｌ（−）−プロリン 和光純薬工業(株)製）０．９ｇ、エタノール５０ｍｌをナス型フラスコに量りとり、７５℃で３時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を１０ｇ得たが、粉末の流動性は良くなかった。
[Comparative Example 1]
According to the composition of Table 1, 9.1 g of vitamin E (trade name: d-α-tocopherol manufactured by Tama Seikagaku Co., Ltd.), proline (trade name: L (−)-proline, manufactured by Wako Pure Chemical Industries, Ltd.) 0.9 g and 50 ml of ethanol were weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure, and then dried under reduced pressure to obtain 10 g of white to light yellow powder, but the fluidity of the powder was not good.
本比較例は、ビタミンＥとプロリンの比が１：０．０９９であり、ビタミンＥの含量が９１％であった。 In this comparative example, the ratio of vitamin E and proline was 1: 0.099, and the content of vitamin E was 91%.
[比較例２]
表２の配合に準じ、プロリンを同じアミノ酸であるグリシン（商品名：グリシン 和光純薬工業(株)製）３ｇに代えた以外は実施例３と同様の操作をしたが、粉末にはならなかった。
[Comparative Example 2]
According to the composition in Table 2, the same operation as in Example 3 was performed except that proline was replaced with 3 g of glycine (trade name: glycine, manufactured by Wako Pure Chemical Industries, Ltd.), which is the same amino acid. It was.
[比較例３〜１６]
表２の配合に準じ、プロリンを同じアミノ酸であるＬ−アラニン（商品名：Ｌ−アラニン 和光純薬工業(株)製）３ｇ(比較例３)、あるいは４−アミノ酪酸（商品名：４−アミノ酪産 和光純薬工業(株)製）３ｇ(比較例４)、あるいはＬ−セリン（商品名：Ｌ−セリン 和光純薬工業(株)製）３ｇ(比較例５)、あるいはＬ−バリン（商品名：Ｌ−バリン 和光純薬工業(株)製）３ｇ(比較例６)、あるいはＬ−スレオニン（商品名：Ｌ−スレオニン 和光純薬工業(株)製）３ｇ(比較例７)、あるいはＬ−システイン（商品名：Ｌ−システイン 和光純薬工業(株)製）３ｇ(比較例８)、あるいはＬ−ロイシン（商品名：Ｌ−ロイシン 和光純薬工業(株)製）３ｇ(比較例９)、あるいはＬ−アスパラギン（商品名：Ｌ−アスパラギン 和光純薬工業(株)製）３ｇ(比較例１０)、あるいはＬ−リシン（商品名：Ｌ−リシン 和光純薬工業(株)製）３ｇ(比較例１１)、あるいはＬ−グルタミン酸（商品名：Ｌ−グルタミン酸 和光純薬工業(株)製）３ｇ(比較例１２)、あるいはＬ−ヒスチジン（商品名：Ｌ−ヒスチジン 和光純薬工業(株)製）３ｇ(比較例１３)、あるいはＬ（−）−フェニルアラニン（商品名：Ｌ（−）−フェニルアラニン 和光純薬工業(株)製）３ｇ(比較例１４)、あるいはＬ（＋）−アルギニン（商品名：Ｌ（＋）−アルギニン 和光純薬工業(株)製）３ｇ(比較例１５)、あるいはＬ−チロシン（商品名：Ｌ−チロシン 和光純薬工業(株)製）３ｇ(比較例１６)に代えた以外は実施例３と同様の操作をしたが、何れも粉末にはならなかった。
[Comparative Examples 3 to 16]
According to the composition of Table 2, 3 g of L-alanine (trade name: L-alanine manufactured by Wako Pure Chemical Industries, Ltd.), which is the same amino acid as proline, (comparative example 3), or 4-aminobutyric acid (trade name: 4- Aminodairy product Wako Pure Chemical Industries, Ltd. 3 g (Comparative Example 4), or L-serine (trade name: L-Serine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 5), or L-valine (Trade name: L-valine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 6), or L-threonine (trade name: L-threonine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 7), Alternatively, L-cysteine (trade name: L-cysteine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 8), or L-leucine (trade name: L-leucine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (comparative) Example 9) or L-asparagine (trade name: L-asparagine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 1) ) Or L-lysine (trade name: L-lysine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 11), or L-glutamic acid (trade name: L-glutamic acid, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 12) or L-histidine (trade name: L-histidine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 13), or L (-)-phenylalanine (trade name: L (-)-phenylalanine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 14), or L (+)-Arginine (trade name: L (+)-Arginine, Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 15), or The same operation as in Example 3 was performed except that 3 g of L-tyrosine (trade name: L-tyrosine, manufactured by Wako Pure Chemical Industries, Ltd.) (Comparative Example 16) was used, but none of the powders became powder.
[比較例１７、１８]
表２の配合に準じ、プロリンを同じアミノ酸であるＬ−トリプトファン（商品名：Ｌ−トリプトファン 和光純薬工業(株)製）４ｇ(比較例１７)、あるいはＬ−シスチン（商品名：Ｌ−シスチン 和光純薬工業(株)製）４ｇ(比較例１８)に代えた以外は実施例２と同様の操作をしたが、何れも粉末にはならなかった。
[Comparative Examples 17 and 18]
According to the composition of Table 2, 4 g of L-tryptophan (trade name: L-tryptophan, manufactured by Wako Pure Chemical Industries, Ltd.) which is the same amino acid as proline (Comparative Example 17), or L-cystine (trade name: L-cystine) The same operation as in Example 2 was performed except that 4 g (Comparative Example 18) was changed to 4 g (Comparative Example 18) manufactured by Wako Pure Chemical Industries, Ltd.
プロリンの代わりに、表２記載の１７種類のアミノ酸を用いて、ビタミンＥとの複合体を形成できるのか実験を行ったが、何れの実験でも粉末にすることができず、このことからビタミンＥとプロリンは特異的に複合体を形成し、粉末になることがわかった。 An experiment was conducted to determine whether a complex with vitamin E could be formed using 17 kinds of amino acids listed in Table 2, instead of proline. And proline were found to form a complex specifically into a powder.
[実験例１]
実施例４において得られた粉末を用いて、粉末中のビタミンＥ含量の測定、安息角、カサ密度、タッピング密度及び融点などの物性値の測定を行った。
[Experiment 1]
Using the powder obtained in Example 4, the vitamin E content in the powder was measured, and the physical properties such as the angle of repose, the bulk density, the tapping density and the melting point were measured.
粉末に含まれるビタミンＥ含量の測定方法は、粉末に対して４０倍量（Ｖ／Ｗ）の５０ｖｏｌ％エタノール水と２０倍量（Ｖ／Ｗ）のヘキサンを用いて分配し、ヘキサンを溶媒留去・乾燥すると粘稠な油を得るので、この油を食品添加物公定書第７版記載の方法でビタミンＥ含量を定量し、粉末を抽出して得られた油量に、抽出した油中のビタミンＥ含量を乗じて得られたビタミンＥ量を、抽出時に用いた粉末量で割った値を百分率で表した値が粉末中のビタミンＥ含量となるので、結果を表３に示した。 The method for measuring the vitamin E content contained in the powder is to use 40 volumes (V / W) of 50 vol% ethanol water and 20 volumes (V / W) of hexane for the powder. Since a viscous oil is obtained when dried and dried, the vitamin E content of this oil is quantified by the method described in the 7th edition of the Food Additives Standard, and the amount of oil obtained by extracting the powder is extracted into the extracted oil. The value obtained by multiplying the amount of vitamin E obtained by multiplying the amount of vitamin E by the amount of powder used at the time of extraction as a percentage is the vitamin E content in the powder. The results are shown in Table 3.
さらには、粉末の流動性を調べるため、ＡＢＤ粉体特性測定器（筒井理化学器械(株)製）を用いて、安息角、カサ密度及びタッピング密度を測定し、結果を表３に示した。 Furthermore, in order to investigate the fluidity of the powder, the angle of repose, the bulk density, and the tapping density were measured using an ABD powder property measuring instrument (manufactured by Tsutsui Chemical Co., Ltd.), and the results are shown in Table 3.
粉末の融点は、ＭＩＣＲＯ ＭＥＬＴＩＮＧ ＰＯＩＮＴ ＡＰＰＡＲＡＴＵＳ（(株)柳本製作所製）を用いて測定し、結果を表３に示した。 The melting point of the powder was measured using MICRO MELTING POINT APPARATUS (manufactured by Yanagimoto Seisakusho Co., Ltd.), and the results are shown in Table 3.
表３の結果より、実施例４の本発明である粉末は、粉末中のビタミンＥ含量は７８％、安息角３９°、カサ密度０．４４ｇ／ｍｌ、タッピング密度０．５３ｇ／ｍｌ及び融点６３〜６５℃となり、ビタミンＥ含量が高く、且つ、流動性の良い粉末であることがわかる。 From the results of Table 3, the powder of the present invention of Example 4 has a vitamin E content of 78%, an angle of repose of 39 °, a bulk density of 0.44 g / ml, a tapping density of 0.53 g / ml, and a melting point of 63. It can be seen that the powder is ˜65 ° C., has a high vitamin E content, and has good fluidity.
Claims (4)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006195602A JP4029109B1 (en) | 2006-07-18 | 2006-07-18 | Complex powder of vitamin E and proline and method for producing the same |
| PCT/JP2007/061686 WO2008010362A1 (en) | 2006-07-18 | 2007-06-05 | Powder of vitamin e/proline complex and method of producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006195602A JP4029109B1 (en) | 2006-07-18 | 2006-07-18 | Complex powder of vitamin E and proline and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP4029109B1 JP4029109B1 (en) | 2008-01-09 |
| JP2008024603A true JP2008024603A (en) | 2008-02-07 |
Family
ID=38956697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006195602A Active JP4029109B1 (en) | 2006-07-18 | 2006-07-18 | Complex powder of vitamin E and proline and method for producing the same |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4029109B1 (en) |
| WO (1) | WO2008010362A1 (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011519886A (en) * | 2008-05-09 | 2011-07-14 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Method for producing intermediate powder formulation and final solid dosage form under application of spray coagulation process |
| US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| WO2019128175A1 (en) | 2017-12-26 | 2019-07-04 | 上海共晶医药科技有限公司 | Cocrystal of tocopherol and proline and preparation method therefor |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201725A (en) * | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | Composition for preventing browning |
| JPS6058918A (en) * | 1983-09-12 | 1985-04-05 | Advance Res & Dev Co Ltd | Additive for medical purposes |
-
2006
- 2006-07-18 JP JP2006195602A patent/JP4029109B1/en active Active
-
2007
- 2007-06-05 WO PCT/JP2007/061686 patent/WO2008010362A1/en active Application Filing
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
| US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
| JP2011519886A (en) * | 2008-05-09 | 2011-07-14 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Method for producing intermediate powder formulation and final solid dosage form under application of spray coagulation process |
| US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| WO2019128175A1 (en) | 2017-12-26 | 2019-07-04 | 上海共晶医药科技有限公司 | Cocrystal of tocopherol and proline and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4029109B1 (en) | 2008-01-09 |
| WO2008010362A1 (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4029109B1 (en) | Complex powder of vitamin E and proline and method for producing the same | |
| Matthäus et al. | Renewable resources from insects: exploitation, properties, and refining of fat obtained by cold‐pressing from Hermetia illucens (Black Soldier Fly) larvae | |
| Mok et al. | Fucoxanthin bioavailability from fucoxanthin-fortified milk: In vivo and in vitro study | |
| WO2004009035A3 (en) | Compositions and products containing enantiomeric equol, and methods for their making | |
| CN109152377A (en) | The method of composition of the preparation comprising omega-fatty acid salt and amine | |
| CN104357595B (en) | Give leather fat of leather shielding ultraviolet rays function and preparation method thereof | |
| Bajza et al. | Thermal and enzymatic recovering of proteins from untanned leather waste | |
| Zhang et al. | Calcium supplements and structure–activity relationship of peptide-calcium chelates: a review | |
| JP2530488B2 (en) | Cosmetics | |
| CN109602621A (en) | A kind of skin care item and preparation method thereof containing choline gallate | |
| Wang et al. | Rheological and physicochemical properties of Spirulina platensis residues-based inks for extrusion 3D food printing | |
| BR0316782A (en) | Fermented milk product, process for preparing a fermented milk product and use of the cnrz 244 strain of lactobacillus helveticus | |
| Airouyuwa et al. | Influence of physicochemical properties of carboxylic acid-based natural deep eutectic solvents (CA-NADES) on extraction and stability of bioactive compounds from date (Phoenix dactylifera L.) seeds: An innovative and sustainable extraction technique | |
| Rondel et al. | Synthesis and properties of lipoamino acid–fatty acid mixtures: influence of the amphiphilic structure | |
| RU2007135735A (en) | SOLID COSMETIC AND THERAPEUTIC COMPOSITIONS SUITABLE FOR APPLICATION ON HUMAN SKIN AND ARE ABLE TO FORM A GEL IN CONTACT WITH WATER | |
| Xie et al. | Solvent-free synthesis of high-purity sucrose fatty acid monoesters and a comparison of their properties with those of their commercial counterparts | |
| CN1068731A (en) | Cosmetic gel | |
| Tossavainen et al. | Chemical composition and biomethane production potential of Euglena gracilis biomass and extraction residue from supercritical CO2 extraction | |
| CN108541775A (en) | A kind of linseed oil and fiery flaxseed oil blending edible oil and preparation method thereof | |
| JP2018140947A (en) | Composition and limonoid characterized by promoting collagen production | |
| JP2014084302A (en) | S-adenosylmethionine-containing yeast and pyrroloquinoline quinone composition | |
| BR0206640A (en) | Creamy food product and process for its preparation | |
| JP2013255512A (en) | Collagen absorption promoting composition | |
| WO2010046298A3 (en) | Improved peptide availability | |
| CN106399438B (en) | Method for preparing rice bran protein ACE inhibitory peptide by compounding high-voltage electric field and enzyme method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071002 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071015 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101019 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4029109 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101019 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111019 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111019 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121019 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131019 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |